CDK12: a potential therapeutic target in cancer

Related Experiment Video

Updated: Dec 6, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.7K

Fatemeh Emadi1, Theodosia Teo1, Muhammed H Rahaman1

  • 1Drug Discovery and Development, University of South Australia, UniSA Clinical and Health Sciences, Adelaide, SA, 5000, Australia.

Drug Discovery Today
|October 10, 2020
PubMed

Insights

Cyclin-dependent kinase (CDK) 12 plays key roles in cancer by regulating DNA damage response and replication. Developing selective CDK12 inhibitors is crucial for effective cancer drug development.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Cyclin-dependent kinase (CDK) 12 is involved in transcription, cell cycle, and proliferation.
  • CDK12 regulates cancer-related genes in DNA damage response (DDR) and replication, maintaining genomic stability.
  • CDK12 can act as an oncogene or tumor suppressor, with dysregulation leading to tumorigenesis.

Purpose of the Study:

  • To review the biological roles of CDK12 in various cancers.
  • To analyze existing CDK12 inhibitors for molecular insights.
  • To guide the development of novel, selective CDK12 inhibitors.

Main Methods:

  • Literature review of CDK12 functions in cancer.
  • Molecular analysis of current nonselective CDK12 inhibitors.
  • Discussion of strategies for rational drug design.

Main Results:

  • CDK12's multifaceted roles in cancer biology are highlighted.
  • Current inhibitors lack selectivity, hindering drug development.
  • Understanding inhibitor mechanisms is key to designing targeted therapies.

Conclusions:

  • Selective CDK12 inhibition presents a promising avenue for cancer therapy.
  • Further research into CDK12's specific roles and inhibitor profiles is warranted.
  • Targeted drug design can overcome limitations of current nonselective inhibitors.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

19.2K
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.2K

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K